Shandong, China

Xianjun Qu

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xianjun Qu: Innovator in Myricetin Derivatives

Introduction

Xianjun Qu is a notable inventor based in Shandong, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of myricetin derivatives. His work focuses on innovative methods for treating colitis and colorectal cancer, showcasing his commitment to advancing medical science.

Latest Patents

Xianjun Qu holds a patent for a myricetin derivative and its preparation method. This invention is aimed at treating colitis, preventing and treating colitis-associated tumorigenesis, and addressing colorectal cancer. The myricetin derivative he developed exhibits excellent water solubility and possesses biological activities that inhibit colitis and prevent tumorigenesis. The preparation method utilizes myricetrin as a starting material, which is both economical and readily available. This method boasts low costs, high yields, and high product purity, making it suitable for large-scale industrial production. The patent represents significant market value and economic prospects.

Career Highlights

Xianjun Qu is affiliated with the Marine Biomedical Research Institute of Qingdao Co., Ltd. His work at this institute has allowed him to focus on innovative research and development in the biomedical field. His contributions have been instrumental in advancing therapeutic options for serious health conditions.

Collaborations

Xianjun Qu has collaborated with notable colleagues, including Wenbao Li and Feng Li. These partnerships have fostered a collaborative environment that enhances research outcomes and innovation.

Conclusion

Xianjun Qu's work in developing myricetin derivatives highlights his innovative spirit and dedication to improving healthcare solutions. His contributions to the field of pharmaceuticals are paving the way for new treatments for colitis and colorectal cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…